Immunotherapy in melanoma: Recent advances and future directions

European Journal of Surgical Oncology

Volumn 43, Issue 3, 2017, Pages 604-611

  Franklin, C ^a,b   Livingstone, E ^a,b   Roesch, A ^a,b   Schilling, B ^a,b   Schadendorf, D ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Immune checkpoint blockade; Immunotherapy; Melanoma; Oncolytic virus

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; ONCOLYTIC VIRUS; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; HUMAN; MELANOMA; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; FORECASTING; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; SKIN NEOPLASMS; TRENDS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; FORECASTING; HUMANS; IMMUNOTHERAPY; MELANOMA; ONCOLYTIC VIROTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 85005950533     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2016.07.145     Document Type: Review

References (35)

1. 1 Colombino, M., Capone, M., Lissia, A., et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 30 (2012), 2522–2529.
2. 2 Chapman, P.B., Hauschild, A., Robert, C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364 (2011), 2507–2516.
3. 3 Hauschild, A., Grob, J.J., Demidov, L.V., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380 (2012), 358–365.
4. 4 Robert, C., Karaszewska, B., Schachter, J., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372 (2015), 30–39.
5. 5 Larkin, J., Ascierto, P.A., Dreno, B., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371 (2014), 1867–1876.
6. 6 Long, G.V., Stroyakovskiy, D., Gogas, H., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386 (2015), 444–451.
7. 7 Weber, J., Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 13:Suppl 4 (2008), 16–25.
8. 8 Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
9. 9 Wolchok, J.D., Hoos, A., O'Day, S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
10. 10 Tchekmedyian, S.G.J., Korman, A., Keler, T., Deo, Y., Davis, T.A., MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. Proc Am Soc Clin Oncol, 2002, 21.
11. 11 Wolchok, J.D., Neyns, B., Linette, G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11 (2010), 155–164.
12. 12 Robert, C., Thomas, L., Bondarenko, I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
13. 13 Weber, J.S., KKC, HA, Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30 (2012), 2691–2697.
14. 14 Schadendorf, D., Hodi, F.S., Robert, C., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
15. 15 Eggermont, A.M., Chiarion-Sileni, V., Grob, J.J., et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16 (2015), 522–530.
16. 16 Keir, M.E., Butte, M.J., Freeman, G.J., Sharpe, A.H., PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26 (2008), 677–704.
17. 17 Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002), 793–800.
18. 18 Ribas, A., Tumor immunotherapy directed at PD-1. N Engl J Med 366 (2012), 2517–2519.
19. 19 Brahmer, J.R., Drake, C.G., Wollner, I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28 (2010), 3167–3175.
20. 20 Lipson, E.J., Sharfman, W.H., Drake, C.G., et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19 (2013), 462–468.
21. 21 Topalian, S.L., Hodi, F.S., Brahmer, J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
22. 22 Topalian, S.L., Sznol, M., McDermott, D.F., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 (2014), 1020–1030.
23. 23 Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
24. 24 Weber, J.S., D'Angelo, S.P., Minor, D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
25. 25 Hamid, O., Robert, C., Daud, A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
26. 26 Robert, C., Ribas, A., Wolchok, J.D., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384 (2014), 1109–1117.
27. 27 Ribas, A., Puzanov, I., Dummer, R., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (2015), 908–918.
28. 28 Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
29. 29 Wolchok, J.D., Kluger, H., Callahan, M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
30. 30 Postow, M.A., Chesney, J., Pavlick, A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
31. 31 Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
32. 32 Andtbacka, R.H., Kaufman, H.L., Collichio, F., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33 (2015), 2780–2788.
33. 33 Kohlhapp, F.J., Kaufman, H.L., Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res 22:5 (2016 Mar 1), 1048–1054.
34. 34 Dharmadhikari, N., Mehnert, J.M., Kaufman, H.L., Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol, 16, 2015, 326.
35. 35 Puzanov, I., Milhem, M.M., Minor, D., et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol, 2016.